Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Martí Carvajal, Arturo J ^a   Anand, Vidhu ^b   Solà, Ivan ^c  

^a Iberoamerican Cochrane Network   (Venezuela)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FEDRATINIB; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; PLACEBO; RUXOLITINIB; UNCLASSIFIED DRUG; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; BONE PAIN; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; HUMAN; LIMB PAIN; MULTICENTER STUDY (TOPIC); MYALGIA; MYELOFIBROSIS; MYELOFIBROSIS SYMPTOM ASSESSMENT FORM; NAUSEA; NEUTROPENIA; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; MORTALITY; PRIMARY MYELOFIBROSIS;

HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944474506     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010298.pub2     Document Type: Review

References (175)

1. Mesa R, Verstovsek S, Gupta V, Mascarenhas J, Atallah E, Sun W, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 1733.
2. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2013;31(10):1285-92. [PUBMED: 23423753]
3. Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011;117(21):4869-77. [PUBMED: 21480207]
4. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leukemia Research 2013;37(8):911-6. [PUBMED: 23684482]
5. 9/L): a comparison to patients with normal or high starting platelet counts. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 176.
6. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120(6):1202-9. [PUBMED: 22718840]
7. Verstovsek S, Mesa R, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 800.
8. Verstovsek S, Mesa RA, Gotlib J, Levy R, Gupta V, DiPersio JF, et al. Clinical burden and progression of myelofibrosis in a controlled study population of placebo-treated patients (COMFORT-I). Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5146.
9. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine 2012;366(9):799-807. [PUBMED: 22375971]
10. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I. Blood. 2011; Vol. 118: 278.
11. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III. study in patients with myelofibrosis. British Journal of Haematology 2013;161(4):508-16. [PUBMED: 23480528]
12. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98(12):1865-71. [PUBMED: 24038026]
13. Verstovsek S, Mesa RA, Gotlib JR, Gupta V, DiPersio JF, Catalano JV for the COMFORT-I Investigators. Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2012; Vol. 30(15 Suppl): 6624.
14. Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF, et al. Results of COMFORT-I, a randomized double-blind phase III. trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). Journal of Clinical Oncology. 2011; Vol. 29 (15 Suppl).
15. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 120: 801.
16. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122(25):4047-53. [PUBMED: 24174625]
17. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II. study. Blood 2014;123(14):2157-60. [PUBMED: 24458439]
18. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine 2012;366(9):787-98. [PUBMED: 22375970]
19. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. Results of a randomized study of the JAK Inhibitor INC424 (Ruxolitinib) compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). http://www.oncuview.tv/portals/0/linkedfiles/COMFORTII_ASCO_2011_Highlight_Slides_Harrison.pdf (accessed 27 February 2013).
20. Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). Journal of Clinical Oncology. 2011; Vol. 29:LBA6501.
21. Harrison CN, Kiladjian J-J, Al-Ali HK, Gisslinger H, Knoops L, Waltzman RJ, et al. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Blood. 2011; Vol. 118: 795.
22. Harrison CN, Kiladjian J-J, Gisslinger H, Niederwieser D, Passamonti F, Waltzman RJ, et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT-II. study. Blood. 2011; Vol. 118: 279.
23. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology 2013;162(2):229-39. [PUBMED: 23672349]
24. Kiladjian JJ, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, et al. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II. study. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings). 2012; Vol. 30: 6626.
25. McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jakel N, Sirulnik A, et al. The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF). Blood (ASH Annual Meeting Abstracts). 2012; Vol. 20: 2838.
26. McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäckel N, Sirulnik A, et al. Anemia and the use of erythropoietic-stimulating agents with ruxolitinib in the COMFORT-II. study. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 5147.
27. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. Leukemia & Lymphoma 2014;55(1):195-7. [PUBMED: 23647081]
28. Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leukemia & Lymphoma 2014;55(1):5-6. [PUBMED: 23829281]
29. 9/l. Journal of Clinical Oncology 2012;30(15 Suppl):TPS6642.
30. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011;118(8):2069-76. [PUBMED: 21725052]
31. le Coutre PD, Gisslinger H, Zachee P, Gupta V, Perez JR, Schenk N, et al. An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). Journal of Clinical Oncology 2012;30(15 Suppl):TPS6640.
32. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, et al. A phase II. trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007;21(9):1964-70. [PUBMED: 17581608]
33. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2014;99(2):292-8. [PUBMED: 23911705]
34. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology 2011;29(7):789-96. [PUBMED: 21220608]
35. Pardanani AD, Gotlib J, Jamieson C, Cortes J, Talpaz M, Stone RM, et al. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood (ASH Annual Meeting Abstracts). 2009; Vol. 112: 755.
36. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013;27(6):1322-7. [PUBMED: 23459451]
37. Santos FPS, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010;115(6):1131-6. [PUBMED: 20008298]
38. 9/L. Journal of Clinical Oncology 2012;30(15 Suppl):TPS6630.
39. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology & Oncology 2013;6(1):81. [: 24283202]
40. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine 2010;363(12):1117-27. [PUBMED: 20843246]
41. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: survival advantage of ruxolitinib therapy. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118: 793.
42. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, et al. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research 2014;38(3):316-22. [PUBMED: 24374145]
43. Pardanani AD, Cortes JE, Cervantes F, Harrison CN, Passamonti F, Lebedinsky C, et al. JAKARTA: A phase III., multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly. Journal of Clinical Oncology 2012;30(15 Suppl):TPS6639.
44. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8. [PUBMED: 12928469]
45. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311(7003):486. [PUBMED: 7647644]
46. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332(7549):1080. [PUBMED: 16675816]
47. Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Statistics in Medicine 2004;23(7):1159-78. [PUBMED: 15057884]
48. Bain BJ. The peripheral blood smear. In: Goldman L, Schafer AS editor(s). Goldman's Cecil Medicine. 24th Edition. Philadelphia, PA: Elsevier & Saunders, 2012:1024-31. [: ISBN 978-0-8089-2437-1]
49. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
50. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115(4):778-82. [PUBMED: 19965680]
51. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22(2):437-8. [PUBMED: 17728787]
52. Barosi G, Cervantes F, Ben-Yehuda D, Panagiotidis P, Perez JR, Orlando-Harper ND, et al. A ruxolitinib individual supply program for patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. Blood (ASH Annual Meeting Abstracts). 2011; Vol. 118:5170.
53. Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy 2011;12(10):1597-611. [PUBMED: 21457082]
54. Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PUBMED: 22511692]
55. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011;25(2):301-4. [PUBMED: 21052089]
56. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
57. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 2013;14(5):365-76. [DOI: 23571845]
58. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 2013;309(8):814-22. [PUBMED: 23443445]
59. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs of Today 2003;39(7):477-95. [PUBMED: 12973399]
60. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-901. [PUBMED: 18988864]
61. Cervantes F, Pereira A. Advances in the understanding and management of primary myelofibrosis. Current Opinion in Oncology 2011;23(6):665-71. [PUBMED: 21892083]
62. Chan AW, TetzlaffJM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet 2013;381(9861):91-2. [PUBMED: 23305999]
63. Chan AW, TetzlaffJM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7. [PUBMED: 23295957]
64. Chan AW, TetzlaffJM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. [PUBMED: 23303884]
65. Biostat, Inc. Comprehensive Meta-Analysis. 2.0. Englewood, NJ: Biostat, Inc, 2005.
66. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/(accessed 29 September 2011). Copenhagen: Central Trial Unit, 2011.
67. Cumsille F, Bangdiwala SI. [Categorizing variables in the statistical analysis of data: consequences for interpreting the results] [Categorización de variables en el análisis estadístico de datos: consecuencias sobre la interpretación de resultados]. Revista Panamericana de Salud Pública 2000;8(5):348-54. [PUBMED: 11190972]
68. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
69. Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu HL, et al. U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clinical Cancer Research 2012;18(12):3212-7. [PUBMED: 22544377]
70. Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One 2013;8(3):e58711. [PUBMED: 23555593]
71. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. American Journal of Kidney Diseases 2001;38(2):415-25. [PUBMED: 11479173]
72. Doucet M, Sismondo S. Evaluating solutions to sponsorship bias. Journal of Medical Ethics 2008;34(8):627-30. [PUBMED: 18667655]
73. Food, Drug Administration. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2007. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf (accessed 22 March 2012).
74. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharmaceutical Statistics 2009;8(1):50-61. [PUBMED: 18389492]
75. Fermi Paradox. www.crystalinks.com/fermiparadox.html (accessed 12 April 2013).
76. Finazzi G, Xu M, Barbui T, Hoffman R. Essential thrombocythemia. In: Hoffman, Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1149-66. [: ISBN 978-0-443-06715-0]
77. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II. error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New England Journal of Medicine 1978;299(13):690-4. [PUBMED: 355881]
78. Gabriel SE, Normand SL. Getting the methods right--the foundation of patient-centered outcomes research. New England Journal of Medicine 2012;367(9):787-90. [PUBMED: 22830434]
79. Godlee F. Outcomes that matter to patients. BMJ 2012;344:e318. [DOI: http://dx.doi.org/10.1136/bmj.e318]
80. Golder S, Loke YK. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?. British Journal of Clinical Pharmacology 2008;66(6):767-73. [PUBMED: 18754841]
81. McMaster University. GRADEpro. (19 March 2015). McMaster University, 2014.
82. Green SB. Design of randomized trials. Epidemiologic Reviews 2002;24(1):4-11. [PUBMED: 12119855]
83. Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, et al. Wintrobe's Clinical Hematology. 12th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2009. [: ISBN 978-0-7817-6507-7]
84. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
85. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
86. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
87. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
88. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
89. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
90. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2. [PUBMED: 21185693]
91. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
92. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
93. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines 12. Preparing Summary of findings tables - binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158-72. [PUBMED: 22609141]
94. Hemming K, Hutton JL. Intrapartum amnioinfusion for meconium-stained amniotic fluid: evidence for small study effect bias?. BJOG 2009;116(1):128-9. [PUBMED: 19087088]
95. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ, Trial attrition study group. Assessing the impact of attrition in randomized controlled trials. Journal of Clinical Epidemiology 2010;63(11):1264-70. [PUBMED: 20573482]
96. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
97. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
98. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
99. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
100. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Statistics in Medicine 2011;30(9):903-21. [PUBMED: 21472757]
101. Hoffman R, Xu M, Barosi G. Primary myelofibrosis. In: Hoffman, Ronald editor(s). Hoffman: Hematology: Basic Principles and Practice. 5th Edition. Philadelphia: Churchill Livingstone Elsevier, 2008:1125-47. [: ISBN 978-0-443-06715-0]
102. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. European Journal of Haematology 2009;82(5):329-38. [PUBMED: 19141119]
103. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
104. Ioannidis JP. Why most published research findings are false. PLoS Medicine 2005;2(8):e124. [PUBMED: 16060722]
105. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology 2008;19(5):640-8. [PUBMED: 18633328]
106. Ioannidis JP. The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
107. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMC Medical Research Methodology 2008;8:60. [PUBMED: 18782430]
108. Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Medical Journal of Australia 2002;177(5):256-7. [PUBMED: 12197821]
109. Lan GKK, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70(3):659-63.
110. Lauer MS. From hot hands to declining effects: the risks of small numbers. Journal of the American College of Cardiology 2012;60(1):72-4. [PUBMED: 22742403]
111. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
112. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70. [PUBMED: 12775614]
113. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
114. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization of quantitative variables. Psychological Methods 2002;7(1):19-40.
115. Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical Cancer Research 2012;18(11):3008-14. [PUBMED: 22474318]
116. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 2013;121(24):4832-7. [PUBMED: 23570800]
117. Mesa R, Gale RP. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leukemia Research 2009;33(9):1156-7. [PUBMED: 19450878]
118. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Research 2009;33(9):1199-203. [PUBMED: 19250674]
119. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. American Journal of Hematology 2010;85(2):129-30. [PUBMED: 20052748]
120. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116(22):4436-8. [PUBMED: 20651074]
121. Mesa RA. The evolving treatment paradigm in myelofibrosis. Leukemia & Lymphoma 2013;54(2):242-51. [PUBMED: 22793267]
122. Mesa RA, Yasothan U, Kirkpatrick P. Ruxolitinib. Nature Reviews. Drug Discovery 2012;11(2):103-4. [PUBMED: 22293561]
123. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13. [PUBMED: 9746022]
124. Moher D, Liberati A, TetzlaffJ, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12. [PUBMED: 19631508]
125. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [PUBMED: 20332511]
126. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140(10):795-801. [PUBMED: 15148066]
127. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5(6):649-55. [PUBMED: 7165009]
128. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncology 2011;7(9):1035-43. [PUBMED: 21919691]
129. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis. Drugs of Today 2011;47(11):817-27. [PUBMED: 22146225]
130. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management 2012;8:95-103. [PUBMED: 22399854]
131. Pardanani A, Tefferi A. Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology 2011;18(2):105-10. [PUBMED: 21245760]
132. Pardanani A. Ruxolitinib for myelofibrosis therapy: current context, pros and cons. Leukemia 2012;26(7):1449-51. [PUBMED: 22285996]
133. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115(9):1703-8. [PUBMED: 20008785]
134. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Current Opinion in Hematology 2012;19(2):117-23. [PUBMED: 22227528]
135. Pastore A, Temussi PA. The two faces of Janus: functional interactions and protein aggregation. Current Opinion in Structural Biology 2012;22(1):30-7. [PUBMED: 22155180]
136. Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: "Our questions, our decisions: Standards for patient-centered outcomes research", 2012. http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 1 April 2013):1-61.
137. Peacock JL, Sauzet O, Ewings SM, Kerry SM. Dichotomising continuous data while retaining statistical power using a distributional approach. Statistics in Medicine 2012;31(26):3089-103. [PUBMED: 22865598]
138. Pereira TV, Ioannidis JP. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. Journal of Clinical Epidemiology 2011;64(10):1060-9. [PUBMED: 21454050]
139. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Controlled Clinical Trials 1997;18(6):580-93, 661-6. [PUBMED: 9408720]
140. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998;351(9095):47-52. [PUBMED: 9433436]
141. Porta M. A Dictionary of Epidemiology. 5th Edition. New York: Oxford University Press, 2008.
142. Prentice RL. Surrogate and mediating endpoints: current status and future directions. Journal of the National Cancer Institute 2009;101(4):216-7. [PUBMED: 19211455]
143. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of Clinical Oncology 2009;27(28):4760-6. [PUBMED: 19720904]
144. Qureshi M, Harrison C. Management of myelofibrosis - where next?. Expert Opinion on Pharmacotherapy 2011;12(10):1453-5. [PUBMED: 21651445]
145. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Journal of Hematology & Oncology 2012;5:43. [PUBMED: 22852872]
146. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
147. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38. [PUBMED: 22945832]
148. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig WD. The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Deutsches Arzteblatt International 2010;107(17):295-301. [PUBMED: 20490338]
149. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International 2010;107(16):279-85. [PUBMED: 20467553]
150. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [PUBMED: 7823387]
151. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology 2012;83(9):1136-45. [PUBMED: 22209716]
152. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. Journal of Endocrinological Investigation 2009;32(8):704-16. [PUBMED: 19494706]
153. Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Current Opinion in Oncology 2011;23(6):609-16. [PUBMED: 21993415]
154. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002. [PUBMED: 21784880]
155. Streiner DL. Breaking up is hard to do: The heartbreak of dichotomizing continuous data. Canadian Journal of Psychiatry 2002;47(3):262-6.
156. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of Clinical Oncology 2009;27(27):4563-9. [PUBMED: 19652059]
157. Tefferi A. How I treat myelofibrosis. Blood 2011;117(13):3494-504. [PUBMED: 21200024]
158. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology 2011;86(12):1017-26. [PUBMED: 22086865]
159. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. New England Journal of Medicine 2011;365(15):1455-7. [PUBMED: 21995409]
160. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clinic Proceedings 2011;86(12):1188-91. [PUBMED: 22034658]
161. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Reviews 2011;25(5):229-37. [PUBMED: 21742423]
162. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012;119(12):2721-30. [PUBMED: 22279053]
163. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90(8):1128-32. [PUBMED: 16079113]
164. Thiele J, Kvasnicka HM. Myelofibrosis - what's in a name? Consensus on definition and EUMNET grading. Pathobiology 2007;74(2):89-96. [PUBMED: 17587880]
165. Thompson JE. JAK protein kinase inhibitors. Drug News & Perspectives 2005;18(5):305-10. [PUBMED: 16193102]
166. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86. [PUBMED: 18824467]
167. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA). 2011. http://ctu.dk/tsa/files/tsa_manual.pdf (accessed 30 April 2012).
168. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One 2011;6(10):e25491. [PUBMED: 22028777]
169. Twombly R. Small study on industry trial sponsorship leads to big questions about quality and bias. Journal of the National Cancer Institute 2007; Vol. 99, issue 13:988-90. [PUBMED: 17596566]
170. Vannucchi AM. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leukemia Research 2009;33(12):1581-3. [PUBMED: 19573914]
171. Wen Q, Goldenson B, Crispino JD. Normal and malignant megakaryopoiesis. Expert Reviews in Molecular Medicine 2011;13:e32. [PUBMED: 22018018]
172. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
173. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5. [PUBMED: 18316340]
174. Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ 2011;343:d7995. [PUBMED: 22205706]
175. Martí-Carvajal AJ, Cardona AF, Anand V, Solà I. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010298]